TRPV1 and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: Among the Dsm5 potential modifier genes, Trpv1 is an intriguing candidate as a proposed target of cannabidiol, an FDA/EMA-approved Dravet syndrome therapeutic (Gray and Whalley 2020).